Business
BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI®
Company remains focused on potential approval and launch of IGALMI® for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home settingNEW HAVEN, Conn., Jan. 07, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced that it plans to submit a supplemental New Drug Application (sNDA) this month seeking the
About this update from Bioxcel Therapeutics, Inc.
[{"type":"image","alt":"BioXcel Therapeutics","displaySize":"","headline":null,"caption":"BioXcel Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":220,"height":123,"url":"https://media.zenfs.com/en/globenewswire.com/184443491f4795fadfc360af09172b87"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Ugin_5Up8vRFuzpQTrOKug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/184443491f4795fadfc360af09172b87","width":220,"height":123}},"lazy":false},{"type":"text","content":"Company remains focused on potential approval and launch of IGALMI® for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting","length":178,"tagName":"p"},{"type":"text","content":"NEW HAVEN, Conn., Jan. 07, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced that it plans to submit a supplemental New Drug Application (sNDA) this month seeking the U.S. Food and Drug Administration’s (FDA) approval of IGALMI® for at-home use in the acute treatment of agitation associated with bipolar disorders or schizophrenia.","length":487,"tagName":"p"},{"type":"text","content":"“We are pleased with the progress towards submission of the sNDA and launch planning,” said Vimal Mehta, Ph.D., Chief Executive Officer of BioXcel Therapeutics. “Based on the accelerated submission timeline, we believe IGALMI could be approved for at-home use as early as 2026. We are now focused on launch planning and look forward to potentially introducing this important treatment option for agitation in the at-home setting, where patients and caregivers need it most and where there are no FDA-approved options currently available." About BXCL501Outside of its approved indication by the U.S. Food and Drug Administration as IGALMI® (dexmedetomidine) sublingual film, BXCL501 is an investigational proprietary, orally dissolving film formulation of dexmedetomidine, a selective alpha-2 adrenergic receptor agonist. BXCL501 is under investigation by BioXcel Therapeutics for the acute treatment of agitation associated with Alzheimer’s dementia and for the acute treatment of agitation associated with bipolar I or II disorder or schizophrenia in...